NKMAX Co. Ltd.

NKMAX Co. Ltd., a biotechnology firm headquartered in Seongnam-si, South Korea, was founded in 2002 and operated as ATGen Co. until its rebranding in 2019. The company specializes in the production and distribution of various biological products. Its portfolio features cutting-edge anti-cancer immunotherapy treatments designed to stimulate the body's immune cells to eradicate malignant cells. NKMAX also offers diagnostic solutions, including natural killer cell activity tests for cancer patients; a notable product in this category is the NK VUE Kit, which precisely quantifies IFN-gamma released by activated NK cells using a minimal blood sample. For bolstering immune health, the company provides NK365, a proprietary blend incorporating vitamins, minerals, and agaricus mushroom extract. Additionally, NKMAX develops recombinant proteins and monoclonal antibodies, and extends its diagnostic expertise to the veterinary sector with NK PUPPY, a test designed to assess canine immunity.

CEO: Sangwoo Park - https://www.nkmax.com